The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma (MPM): Clinical results of a single-center trial.
Wieneke A. Buikhuisen
No relevant relationships to disclose
Andrew D. Vincent
No relevant relationships to disclose
Marion M. Scharpfenecker
No relevant relationships to disclose
Catharina M. Korse
No relevant relationships to disclose
Arjan W. Griffioen
No relevant relationships to disclose
Renee van Pel
No relevant relationships to disclose
Paul Baas
No relevant relationships to disclose